Used in the treatment of ALK-positive non-small cell lung cancer, this compound acts as a potent inhibitor of the anaplastic lymphoma kinase (ALK) enzyme. It is particularly effective against tumors that have developed resistance to earlier generation ALK inhibitors. Its application extends to patients with metastatic disease where targeted therapy is required to suppress tumor growth and improve progression-free survival. Due to its ability to cross the blood-brain barrier, it shows significant activity in controlling central nervous system metastases, which are common in advanced stages of lung cancer. The compound is administered orally and designed for chronic use under medical supervision.